GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV

Valérie Martel-Laferrière; Douglas T. Dieterich

doi:10.2217/fvl.12.34

GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV

Valérie Martel-Laferrière, Douglas T. Dieterich

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Despite the approval of the protease inhibitors telaprevir and boceprevir, the treatment of hepatitis C remains difficult to manage and sustained virologic response rates have room for further improvement. GS-7977 is a nucleotide analog NS5B inhibitor currently in Phase III trials. It offers great hope in addressing the problems currently associated with pegylated interferon and protease inhibitor-based therapies. The purpose of this article is to review the development of GS-7977, the information currently available in the public domain concerning its pharmacokinetic, clinical efficacy and side-effect profile, and to evaluate the future of this drug and its integration into the hepatitis C treatment paradigm.

Original language	English
Pages (from-to)	537-546
Number of pages	10
Journal	Future Virology
Volume	7
Issue number	6
DOIs	https://doi.org/10.2217/fvl.12.34
State	Published - Jun 2012

Keywords

GS-7977
GS-9851
NS5B polymerase inhibitor
PSI-7977
hepatitis C
nucleotide analog

Access to Document

10.2217/fvl.12.34

Cite this

@article{a0ba95a0004f4976b26c4190ec117c7a,

title = "GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV",

abstract = "Despite the approval of the protease inhibitors telaprevir and boceprevir, the treatment of hepatitis C remains difficult to manage and sustained virologic response rates have room for further improvement. GS-7977 is a nucleotide analog NS5B inhibitor currently in Phase III trials. It offers great hope in addressing the problems currently associated with pegylated interferon and protease inhibitor-based therapies. The purpose of this article is to review the development of GS-7977, the information currently available in the public domain concerning its pharmacokinetic, clinical efficacy and side-effect profile, and to evaluate the future of this drug and its integration into the hepatitis C treatment paradigm.",

keywords = "GS-7977, GS-9851, NS5B polymerase inhibitor, PSI-7977, hepatitis C, nucleotide analog",

author = "Val{\'e}rie Martel-Laferri{\`e}re and Dieterich, {Douglas T.}",

year = "2012",

month = jun,

doi = "10.2217/fvl.12.34",

language = "English",

volume = "7",

pages = "537--546",

journal = "Future Virology",

issn = "1746-0794",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - GS-7977

T2 - A promising nucleotide analog NS5B polymerase inhibitor of HCV

AU - Martel-Laferrière, Valérie

AU - Dieterich, Douglas T.

PY - 2012/6

Y1 - 2012/6

N2 - Despite the approval of the protease inhibitors telaprevir and boceprevir, the treatment of hepatitis C remains difficult to manage and sustained virologic response rates have room for further improvement. GS-7977 is a nucleotide analog NS5B inhibitor currently in Phase III trials. It offers great hope in addressing the problems currently associated with pegylated interferon and protease inhibitor-based therapies. The purpose of this article is to review the development of GS-7977, the information currently available in the public domain concerning its pharmacokinetic, clinical efficacy and side-effect profile, and to evaluate the future of this drug and its integration into the hepatitis C treatment paradigm.

AB - Despite the approval of the protease inhibitors telaprevir and boceprevir, the treatment of hepatitis C remains difficult to manage and sustained virologic response rates have room for further improvement. GS-7977 is a nucleotide analog NS5B inhibitor currently in Phase III trials. It offers great hope in addressing the problems currently associated with pegylated interferon and protease inhibitor-based therapies. The purpose of this article is to review the development of GS-7977, the information currently available in the public domain concerning its pharmacokinetic, clinical efficacy and side-effect profile, and to evaluate the future of this drug and its integration into the hepatitis C treatment paradigm.

KW - GS-7977

KW - GS-9851

KW - NS5B polymerase inhibitor

KW - PSI-7977

KW - hepatitis C

KW - nucleotide analog

UR - http://www.scopus.com/inward/record.url?scp=84862003649&partnerID=8YFLogxK

U2 - 10.2217/fvl.12.34

DO - 10.2217/fvl.12.34

M3 - Review article

AN - SCOPUS:84862003649

SN - 1746-0794

VL - 7

SP - 537

EP - 546

JO - Future Virology

JF - Future Virology

IS - 6

ER -

GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV

Abstract

Keywords

Access to Document

Fingerprint

Cite this